The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksODX.L Regulatory News (ODX)

  • There is currently no data for ODX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK-RTC Update

17 Nov 2020 07:45

RNS Number : 5541F
Omega Diagnostics Group PLC
17 November 2020
 

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

 

UK-RTC Update

 

Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, notes the press release issued today by the UK Rapid Test Consortium ("UK-RTC"), of which Omega is a partner.

 

The UK-RTC press release announces that Abingdon Health ("Abingdon") has received confirmation from the US Food and Drug Administration ("FDA") that Abingdon has completed the notification process under the FDA's Policy for Coronavirus Disease Tests During the Public Health Emergency ("the Policy").

 

The Policy states that the FDA does not intend to object to a manufacturer distributing serology tests to laboratories that are certified under CLIA1 certification to perform high complexity testing where the test has been validated and while the manufacturer is preparing its Emergency Use Authorization ("EUA") request.

 

Abingdon has submitted an EUA to the FDA for the AbC-19™ Rapid Test as a point of care test and the Company looks forward to learning how the EUA procedure progresses.

 

A full copy of the UK-RTC press release is at the bottom of this announcement.

 

1 CLIA or the Clinical Laboratory Improvement Amendments (42 CFR Part 493) are those regulations that were established in 1988 for the regulation and quality assurance of human specimens within clinical laboratory environments.

 

Contacts: 

 

Omega Diagnostics Group PLC

Tel: 01259 763 030

Bill Rhodes, Interim Non-Executive Chairman

Colin King, Chief Executive

www.omegadiagnostics.com

Kieron Harbinson, Group Finance Director

 

 

 

finnCap Ltd

Tel: 020 7220 0500

Geoff Nash/Edward Whiley (Corporate Finance)

 

Alice Lane (ECM)

 

 

 

Walbrook PR Limited

Tel: 020 7933 8780 or omega@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 

 

Press release from the UK-RTC (issued on 17 November 2020)

 

York, U.K. 17 November 2020: Abingdon Health ("Abingdon" or "the Company"), UK-based developer and manufacturer of lateral flow tests and smartphone reader solutions, today announces that it has been notified by the US Food and Drug Administration (FDA) that it has completed the Section IV.D notification process. This enables the Company to distribute its UK-RTC AbC19™ Rapid Test in the USA to laboratories certified under CLIA and to healthcare workers, for point of care testing covered by a laboratory's CLIA certification for high complexity testing. Distribution of the test will be through CIGA Healthcare, a member of the UK-RTC.

 

Section IV.D of the FDA's Policy for Coronavirus Disease Tests During the Public Health Emergency (Revised) states that the FDA does not intend to object to a manufacturer distributing serology tests to laboratories that are certified under CLIA certification to perform high complexity testing where the test has been validated and while the manufacturer is preparing its Emergency Use Authorization ("EUA") request. An EUA has been submitted to the FDA for the AbC-19™ Rapid Test as a point of care test and dialogue with the FDA is progressing.

 

Leigh Thomas, SVP Director of Global Sales of Abingdon Health said, "Today's news allows us to immediately make the AbC19™ Rapid Test available to CLIA testing labs in the United States and is the latest milestone on the path to receiving an EUA for the AbC19™ Rapid Test. Abingdon Health and our consortium partners in the UK-RTC remain committed to the wide deployment of the AbC19™ Rapid Test and continue to work with regulators both in the UK and internationally. "

 

For more information please contact:

 

Abingdon Health

+44 (0) 1904 406 082

Chris Yates, CEO

info@abingdonhealth.com

 

 

Consilium Strategic Communications

+44 (0) 203 709 5700

Mary-Jane Elliott

abingdonhealth@consilium-comms.com

Matthew Neal

 

 

 

About Abingdon Health

 

Abingdon is a UK-based developer and manufacturer of lateral flow tests and smartphone reader solutions. Abingdon offers development and manufacturing services for customers looking to develop new assays or looking to transfer existing laboratory-based assays to a lateral flow format. Abingdon takes projects from initial concept through to routine and large-scale manufacturing. Abingdon is headquartered in York, England.

 

About UK RTC

 

The UK-RTC was established by Abingdon Health, Omega Diagnostics, BBI Solutions, CIGA Healthcare and Oxford University.

 

About AbC19™ Rapid Test

 

The AbC-19™ IgG lateral flow assay is targeted at IgG antibodies to the full spike protein of SARS-CoV-2 (COVID19) to indicate a measure of immune response (aligned with neutralizing antibodies).

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAFFASWWESSEDF
Date   Source Headline
12th Nov 202010:04 amRNSResponse to media comment
12th Nov 20209:05 amRNSSecond Price Monitoring Extn
12th Nov 20209:00 amRNSPrice Monitoring Extension
11th Nov 20207:00 amRNSInvestor Presentation - Q&A update
10th Nov 20202:00 pmRNSPrice Monitoring Extension
10th Nov 202011:05 amRNSSecond Price Monitoring Extn
10th Nov 202011:01 amRNSPrice Monitoring Extension
9th Nov 20202:05 pmRNSSecond Price Monitoring Extn
9th Nov 20202:00 pmRNSPrice Monitoring Extension
9th Nov 202010:45 amRNSExercise of Options and Total Voting Rights
6th Nov 20209:00 amRNSExercise of Options and Total Voting Rights
3rd Nov 20207:00 amRNSChinese approval for Food Detective® test
30th Oct 20203:00 pmRNSExercise of Options and Total Voting Rights
29th Oct 20206:07 pmRNSHolding(s) in Company
28th Oct 20207:00 amRNSTrading update and notice of interim results
20th Oct 202011:00 amRNSExercise of Options and Total Voting Rights
20th Oct 20207:00 amRNSNotice of Trading Update and Investor Presentation
19th Oct 20207:00 amRNSUK-RTC contract for the Supply of Goods
14th Oct 20207:45 amRNSExercise of Options and Total Voting Rights
9th Oct 20204:15 pmRNSExercise of Options and Total Voting Rights
7th Oct 20207:00 amRNSUK Government contract for UK-RTC
6th Oct 20205:45 pmRNSHolding(s) in Company
6th Oct 20204:46 pmRNSUK Government contract for UK-RTC
6th Oct 20204:41 pmRNSSecond Price Monitoring Extn
6th Oct 20204:35 pmRNSPrice Monitoring Extension
2nd Oct 202012:00 pmRNSPreliminary report published by Ulster University
2nd Oct 202011:05 amRNSSecond Price Monitoring Extn
2nd Oct 202011:00 amRNSPrice Monitoring Extension
2nd Oct 20209:05 amRNSSecond Price Monitoring Extn
2nd Oct 20209:00 amRNSPrice Monitoring Extension
29th Sep 20207:00 amRNSInvestor Presentation
24th Sep 20202:05 pmRNSSecond Price Monitoring Extn
24th Sep 20202:00 pmRNSPrice Monitoring Extension
15th Sep 20205:51 pmRNSExercise of Options and Total Voting Rights
15th Sep 20209:45 amRNSHolding(s) in Company
14th Sep 20204:41 pmRNSSecond Price Monitoring Extn
14th Sep 20204:36 pmRNSPrice Monitoring Extension
14th Sep 20202:05 pmRNSSecond Price Monitoring Extn
14th Sep 20202:01 pmRNSPrice Monitoring Extension
14th Sep 20207:00 amRNSExercise of Options and Total Voting Rights
10th Sep 202010:11 amRNSHolding(s) in Company
7th Sep 20202:33 pmRNSStmnt re Share Price Movement
7th Sep 20207:00 amRNSCompletion of AbC-19 self-test usability study
3rd Sep 20207:00 amRNSCE-Mark for Mologic COVID-19 antibody test
1st Sep 20204:07 pmRNSExercise of Options and Total Voting Rights
28th Aug 20209:45 amRNSHolding(s) in Company
26th Aug 202011:20 amRNSResult of AGM
26th Aug 20207:00 amRNSExercise of Options and Total Voting Rights
24th Aug 20209:30 amRNSExercise of Options and Total Voting Rights
21st Aug 20207:00 amRNSWHO Prequalification received

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.